Bioprinting and Lab Automation · NASDAQ STOCKHOLM: BICO
BICO Group: CELLINK bioprinting and bioinks inside a restructuring life-science automation platform.
CELLINK combines extrusion and light-based bioprinters, bioinks, biomaterials and application protocols for 3D cell culture. The bottleneck is preserving cell viability, geometry and reproducibility while integrating printed models into pharmaceutical, biotech and academic workflows.
As of: 18 October 2026 (key metrics updated to Q2 2026; other figures as of 18 July 2026) · Profile: Bioprinting and laboratory workflow · Recommendation: None
Company Signal Monitor
LAST VERIFIED / REVIEWED
2026-10-18 (Q2 2026 key metrics)
WHAT CHANGED
NEXT CATALYST TO MONITOR
Serial production volumes, regulatory / customer adoption, workflow economics, recurring consumables and disclosed AM contribution.
Quick research snapshot
AM exposure: High
Pure-play score: 3 / 5
Bottleneck score: 3 / 5
Evidence: Pilot
Financial materiality: Emerging
Main risk: Cash burn, portfolio restructuring and research-market cyclicality.
Research verdict: BICO retains meaningful bioprinting, bioink and lab-automation assets, but the investment case depends on proving focused growth, cash discipline and durable demand after portfolio simplification.
Investor read
BICO turned adjusted EBITDA positive in Q2 2026, but remained loss-making at the net level. Net sales were SEK 336.1 million, organic growth was 7.3% and adjusted EBITDA improved to SEK 20.1 million from SEK −49.7 million.
Second-quarter restructuring costs fell to SEK 4.5 million, but operating cash flow was SEK −53.0 million. First-half net sales were SEK 666.0 million and adjusted EBITDA SEK 8.7 million; net cash was SEK 207.1 million at 30 June 2026. Earlier in 2026, BICO refinanced with €40 million of senior secured bonds and fully repaid SEK 1.008 billion of convertible debt.
CELLINK remains the clearest additive-manufacturing exposure inside the group. Its printers and bioinks support 3D cell models, tissue engineering, organoids and drug-discovery workflows. The investment outcome, however, depends more on portfolio focus, lab-automation demand, cost reduction, liquidity and sustainable profitability than on bioprinting industry narratives.
Subscribe to continue reading
Subscribe to get access to the rest of this post and other subscriber-only content.